This is a multicenter, multinational, retrospective cohort study of Hispanic patients treated with Osimertinib as first-line for EGFR-mutated NSCLC....Identified mutations included EGFR Exon 19 deletions and EGFR pL858R point mutations....Factors which negatively affected PFS included presence of liver metastases at diagnosis and a tumor mutational burden > 5 mut/Mb….Liver metastases and a higher tumor mutation burden were associated with a lower PFS.